Last reviewed · How we verify
L-VA dual therapy
At a glance
| Generic name | L-VA dual therapy |
|---|---|
| Also known as | L-VA |
| Sponsor | The First Affiliated Hospital of Nanchang University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- VA Dual Sequential Therapy (PHASE4)
- Helicobacter Pylori and Vonoprazan Dual Therapy (PHASE4)
- Optimization of Vonoprazan--amoxicillin Dual Therapy for Eradicating Helicobacter Pyloriinfection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-VA dual therapy CI brief — competitive landscape report
- L-VA dual therapy updates RSS · CI watch RSS
- The First Affiliated Hospital of Nanchang University portfolio CI